Michael S. Rosol
2020
In 2020, Michael S. Rosol earned a total compensation of $301.6K as Chief Medical Officer at Navidea Biopharmaceuticals, a 21% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $54,710 |
|---|---|
| Option Awards | $19,118 |
| Salary | $223,333 |
| Other | $4,409 |
| Total | $301,570 |
Rosol received $223.3K in salary, accounting for 74% of the total pay in 2020.
Rosol also received $54.7K in non-equity incentive plan, $19.1K in option awards and $4.4K in other compensation.
Rankings
In 2020, Michael S. Rosol's compensation ranked 12,114th out of 13,090 executives tracked by ExecPay. In other words, Rosol earned more than 7.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,114 out of 13,090 | 8th |
Division Manufacturing | 5,178 out of 5,617 | 8th |
Major group Chemicals And Allied Products | 2,101 out of 2,248 | 7th |
Industry group Drugs | 1,828 out of 1,948 | 6th |
Industry In Vitro and In Vivo Diagnostic Substances | 54 out of 60 | 10th |
Source: SEC filing on August 2, 2021.
Rosol's colleagues
We found three more compensation records of executives who worked with Michael S. Rosol at Navidea Biopharmaceuticals in 2020.
News
Navidea Biopharmaceuticals Chief Medical Officer Michael Rosol's 2022 pay slips 8% to $430K
October 5, 2023
Navidea Biopharmaceuticals CEO Jed Latkin's 2021 pay rises 10% to $1.3M
October 24, 2022
Navidea Biopharmaceuticals CEO Jed Latkin's 2020 pay jumps 66% to $1.2M
August 2, 2021
Navidea Biopharmaceuticals CEO Jed Latkin's 2019 pay rises 16% to $740K
July 31, 2020
Navidea Biopharmaceuticals CEO Michael Goldberg's 2018 pay jumps 76% to $1.5M
June 28, 2019